Clinical Study | Office of Clinical Research

A Phase 3 Double-Blind, Placebo Controlled, Parallel Group Study Of A Disease Modifying Agent In Subjects With Early Parkinson Disease

Posted Date: May 15, 2019

Investigator: Alok Sahay
Type of Study: Drug

The purpose of this study is to determine if an investigational drug called isradipine is safe and helpful in slowing the rate of PD decline. Isradipine has been approved by the Food and Drug Administration (FDA) to treat high blood pressure but is considered investigational in this study, as it ha

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Have Been Diagnosed With Parkins

Keywords:

Sahay, Early Stages Of Park, Newly Diagnosed, Isradipine, Parkinson's Disease

For More Information:

Hilary Perez
(513) 558-0112
hilary.perez@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List